- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 232946, 16 pages
Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine
School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong
Received 17 September 2013; Revised 27 December 2013; Accepted 15 January 2014; Published 13 March 2014
Academic Editor: Min Li
Copyright © 2014 Chien-shan Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Molecular targeted therapy has been developed for cancer chemoprevention and treatment. Cancer cells process a fundamental change in its bioenergetic metabolism from normal cells on an altered lipid metabolism, also known as the de novo fatty acid synthesis, for sustaining their high proliferation rates. Fatty acid synthesis is now associated with clinically aggressive tumor behavior and tumor cell growth and has become a novel target pathway for chemotherapy development. Although the underlying mechanisms of the altered de novo fatty acid synthesis still remains unclear, recent progress has shown that by targeting Fatty acid synthase (FASN), a key enzyme that catalyzes the synthesis of endogenous long chain fatty acid could be a critical target for drug discovery. However, relatively few FASN inhibitors have been discovered. With the long history of clinical practices and numerous histological case study reports, traditional Chinese medicine enjoys an important role in seeking bioactive anticancer natural compounds. Herein, we will give an overall picture of the current progress of molecular targeted therapy in cancer fatty acid synthesis, describe the advances in the research on natural products-derived FASN inhibitors and their potential for enhancing our understanding of fatty acids in tumor biology, and may provide new therapeutic moieties for breast cancer patient care.
1.1. Epidemiology of Breast Cancer
Breast cancer is the most prevalent cancer and the second leading cause of mortality in women worldwide . According to the World Cancer Report , breast cancer comprises 22.9% of all cancers in women with an estimated 1.4 million new cases annually, resulting in more than 458,000 deaths in 2008 . It was estimated that more than 1.6 million new cases of breast cancer emerged worldwide in 2010 [1, 3]. Since most breast cancers primarily affect women aged 50 and older, there is a clear relationship between menopause and breast cancer incidence [3–5]. During and after the onset of menopause, changes in hormonal status and in other metabolic processes contribute to the formation of a favorable microenvironment for the development of breast cancer [5, 6]. Several breast cancer treatment options have been considered to be conventional strategies in the last century, namely, mastectomy, chemotherapy, and radiotherapy, or a combination of the three . With the rapid development of molecular medicines, novel therapeutic approaches, such as hormonal therapy and molecular targeted therapy, have been proposed to improve clinical outcome; however, the outcome of such approaches is still not ideal [3, 5, 7].
1.2. Role of TCM in Drug Development
Over the past few years, the development of complementary and alternative medicine (CAM) has drawn great attention in cancer research [8–12]. According to Newman and Cragg (2012), of the 175 small molecules approved worldwide as antitumor drugs during the period from 1981 to 2010, among the 74.8% nonsynthetic drugs, 85, or 48.6%, of them are either natural products or directly derived from natural products . During the period from 2002 to 2010, of the 110 new drugs approved for cancer treatment, 37 of them originated from natural products . TCM has thousands of years of experimentation on human beings. It has recently proved to be an important source for herb selection for drug discovery. In addition, TCM formulas provide promising sources for a more effective and less toxic treatment option for cancer [8, 10, 14–16]. The increasing interest and progress in seeking natural products has not only provided a chemical understanding of herbal drugs and their antitumor function but also contributed to the chemical bank for drug discovery [8, 13].
1.3. Obesity and Breast Cancer
In recent years, there has been increasing interest in the relationship between obesity and cancer. Obesity has been identified as the second leading cancer risk factor, after tobacco, especially for breast cancer [17, 18]. Statistics on breast cancer incidence and body fat indicate that those who reside in certain geographical areas, characterized by consumption of a more energy-dense diet, are at higher risk for breast cancer occurrence [1, 3, 19]. In addition, there is also a relation between body size and breast cancer risk. Women with a BMI of 30 versus 20.0–24.9 kg/m2 have an 82% increased risk for advanced cancer and a 22% increased risk for localized cancer [4, 19–21]. De novo lipogenesis, also known as de novo fatty acid synthesis, is the metabolic pathway synthesizing fatty acids, one of the essential substances for mammals, from nonlipid precursors, which is then incorporated with dietary and adipose tissue-derived fatty acid to produce triglyceride for energy storage that occurs in both liver and adipose tissue [22–24]. Adipose tissue expands to accommodate the excessive endogenous and exogenous lipid synthesized [22, 24]. De novo fatty acid synthesis is a highly regulated metabolic process and any of its dysregulation may result in various diseases [22, 25, 26]. An increase in de novo fatty acid synthesis plays an important role in increased fat mass and is an important contributor to pathological obesity [4, 22]. Obesity may affect not only the occurrence of breast cancer but also the prognosis of it, due to its influence on multiple pathways, such as hormonal influence, associated adverse disease features, and other yet unknown mechanisms [17, 21, 27–29]. There may be an interrelationship between obesity, altered lipid metabolism, and breast cancer risk, disease occurrence, and progression [4, 17, 21]. Therefore, the prevention of obesity and therapeutic approach of treating lipid metabolism disorders have risen as new approaches towards the prevention of breast cancer.
2. FASN as a Target for Cancer Therapy
2.1. Abnormal Fatty Acid Synthesis in Breast Cancer
Fatty acid is one of the essential substances for mammals . It originates both externally (from a dietary source) and internally (synthesized by the de novo fatty acid synthesis) [34–37]. The internal sources of fatty acid, its related enzymes, and its relation to breast cancer tumorigenesis are the focus of discussions, rather than its external source [38, 39]. Cancer cells differ from normal cells in several ways . There is a fundamental difference in the bioenergetic metabolism of aggressive cancer cells compared to normal cells . Cancer cells, in order to sustain their high proliferation rates, rely not only on glycolysis, which is known as the “Warburg Effect”, but also on an altered lipid metabolism [15, 39]. Whereas normal cells prefer to utilize exogenous fatty acid from dietary sources cancer cells utilize a high rate of de novo fatty acid synthesis independent of dietary fat and independent, it appears, of hormonal regulation in many cancers, such as colon cancer and breast cancer [17, 40, 41]. The high rate of de novo synthesis generates essential lipids that are critical for the formation of cell membrane and produces extra energy for cancer proliferation and progression [22, 25, 42]. In contrast to fatty acid synthesis being downregulated in most normal human tissues, precancerous lesion and cancer cells upregulate fatty acid synthesis resulting in the high expression of FASN independent of dietary fat and independent of hormonal regulation in breast cancer (Figure 1) [17, 43].
2.2. Highly Expressed FASN in Breast Cancer
Research has shown that FASN is highly expressed in the hepatocytes and adipocytes of obese patients and in various kinds of cancer cells [17, 44, 45]. Therefore, targeting FASN has come to the attention of many in the drug industry due to the discovery that the inhibition of de novo synthesis of fatty acid can be used to treat cancer patients [17, 46]. Since the 1980s, researchers have identified FASN in various cancers including breast cancer, colon cancer, prostate cancer, ovarian cancer, and endometrium cancer [33, 42, 47]. The aforementioned cancers have shown that the FASN expression in these cancerous cells is significantly higher than that in the surrounding normal tissues . Research has also shown that, through the inhibition of FASN activity or the reduction of its expression, cancer growth could be effectively reduced or apoptosis could be induced [23, 49–51]. However, the underlying mechanism is still under investigation. Some researchers claim that the inhibition of FASN will reduce the formation of essential fatty acid that is needed for the growth of cell membrane and for energy supply, which may be the cause of cancer cell apoptosis [34, 48, 52–54]. Other research findings suspect that the rise in Malonyl-CoA concentration is the trigger for cell apoptosis [53, 55]. Another research has shown that, after FASN inhibition, the growth of the cancer cell remains at G0 phase, showing that fatty acid synthesis is related to cancer cell cycle [46, 56, 57]. In short, the inhibition of FASN can effectively and widely inhibit the DNA replication of cancer cells and delay the S phase in the cell cycle, demonstrating that the pathway of fatty acid synthesis and DNA synthesis activity is related to the growth of cancer cells [58, 59].
In breast cancer, FASN is found to be highly expressed in various breast cancer cell lines, including hormone-independent SKBR3 and hormone-dependent MCF-7 and ZR-75-1 cells [45, 48, 60]. Among hormone-independent and hormone-dependent cell lines, hormone-independent breast cancer cells SKBR3 expressed higher (~2.5-fold) levels of FASN compared to hormone-dependent breast cancer cells [36, 61]. Aside from FASN expression differences between hormone-dependent and hormone-independent cell lines, FASN levels also increased with each successive tumor stage . Research has demonstrated that the inhibition of fatty acid synthesis induces apoptosis and creates cytotoxicity which is likely to trigger cell death as a result of the accumulation of the substrate Malonyl-CoA (Figure 1) [30, 31]. However, scientists have not yet come to the agreement on the reason why and the specific mechanism by which the inhibition of fatty acid kills cancer cells [55, 62–64].
2.3. The Structure of FASN
Fatty acid synthase (FASN) is the key enzyme for de novo fatty acid synthesis and it catalyzes Acetyl-CoA and Malonyl-CoA to form Palmitate and 16-carbon long fatty acid [31, 65]. FASN has seven functional domains, namely, acyl carrier protein (ACP), Malonyl/acetyltransferase (MAT), ketoacyl synthase (KS), ketoacyl reductase (KR), dehydrase (DH), enoyl reductase (ER), and thioesterase (TE) [33, 35, 66]. It can be divided into two subtypes, types II and I. FASN in bacteria and plants is type II FASN with the seven functional domains independent of one another, which form a multicatalytic function system. On the other hand, FASN in humans and other mammals belongs to type I and is encoded by the FASN gene and composed of two identical 272 kDa multifunctional polypeptides, where the seven functional domains form a single bond [33, 37, 49, 66]. A person with sufficient nutrition who consumes a balanced diet undergoes little de novo synthesis of fatty acid. In such case, FASN expression is controlled at a low level because dietary lipid will provide the fatty acid needed for normal body functions [25, 42, 47, 54, 58, 67]. FASN has three main functions: energy storage, synthesis of fat, and lactation [33, 47, 58]. In highly lipogenic tissues, de novo fatty acid synthesis produces fat from excess carbon or energy intake and stores it as triglycerides [22, 68]. In a lactating female, FASN produces medium chain fatty acids along with thioesterase-II and this enables the baby to easily digest the milk [34–36]. Under normal conditions, FASN is regulated by one’s diet and hormones. All carbohydrate intake, thyroid hormone, insulin, and glucocorticoid can up-regulate fatty acid synthesis, while unsaturated fatty acid, cAMP, and glucagon can down-regulate FASN and fatty acid synthesis [4, 42, 45, 69, 70].
2.4. The Metabolism and Expression of FASN
In the last decade, numerous studies have focused on the metabolic alternation of adaptation of cancer cells . Cancer cells possess the feature of high proliferation differentiation . Cells constantly divide, grow, and absorb external nutrition, while in the meantime self-synthesizing essential material for growth [72, 73]. De novo fatty acid synthesis is an important hallmark of cancer cells setting it apart from normal cells . Lipids are the main component for the composition of cell membrane and are essential for cell division [27, 74, 75]. Palmitate is the primary synthesized 16-carbon fatty acid, from which other forms of lipids are also formed . FASN is the key enzyme for the synthesis of palmitate and affects the amount of palmitate formed (Figure 2) [18, 35, 42, 44]. FASN is expressed in most of cancer cells, for example, breast cancer cells, and has a low expression in normal cells [33, 66]. With de novo fatty acid synthesis, tumor cells endogenously synthesize extra fatty acid allowing them to sustain higher proliferation rates and faster growth [25, 77]. Therefore, targeting fatty acid synthase can be an important strategy for cancer prevention and treatment.
2.5. Signaling Pathway and Regulation of FASN
The overexpression of FASN allows for the de novo synthesis of essential lipids for the formation of cell membrane and for the production of extra energy via beta-oxidation and lipid modification of proteins [55, 71, 78]. Although the mechanisms for tumor related FASN overexpression are still unclear, two main mechanisms have been proposed. The first one is the growth factor, which binds to growth factor receptor, activating their downstream PI3k-Akt and ERK1 (and ERK2) signal transduction pathway (Figure 2) [34, 42, 45, 47, 68]. The FASN expression is regulated by several growth factors, including epidermal growth factor receptor (EGFR), HER2, steroid hormone, and steroid hormone receptors (such as ER, PR, and AR) [27, 47, 55, 62, 77]. However, the regulation of FASN expression by these growth factors is rather complicated. FASN expression and growth factor-dependent signaling can be coregulated [42, 49, 50]. For example, through downstream PI3K signaling, HER2 regulates FASN expression; meanwhile, reports also demonstrate that HER2 expression is regulated by FASN expression [45, 57, 64]. HER2 is an overexpressed gene in cancer cells [7, 38, 62, 77]. HER2 is the Tyrosine kinase receptor, which belongs to erbB family [23, 62, 63]. It is similar to the epithelial growth factor receptor and is also involved with regulative cell growth and division . HER2 is expressed in various types of cancer cells [55, 62]. Through overexpressing HER2, cancer cells can produce drug tolerance toward chemo drugs and are related to poor prognosis in cancer patients. Recent studies have shown that FASN and HER2 are both overexpressed in certain types of cancer cells [46, 55, 62, 77]. Inhibiting FASN by either drug or gene silencing can inhibit HER2 expression; meanwhile, HER2 overexpression leads to an increase expression of FASN, indicating that there is a bidirectional regulation mechanism between FASN and HER2 (Figure 3) [25, 34–36, 79].
Recent studies have shown that FASN expression can be not only regulated by SPEBT-1c but also controlled by other transcription factors, such as p53 family proteins and the lipogenesis-related nuclear protein, SPOT14, which is overexpressed in breast cancer [25, 47, 79, 80]. The second mechanism is one whereby steroid hormones binding with steroid hormone receptors activate similar pathways . These two pathways stimulate FASN expression by the gene modulation and/or the nuclear maturation of the sterol regulatory element-binding protein 1c (SREBP1C), which is a transcription factor that activates FASN by binding to its promoter region, which contains sterol regulatory elements [32, 35, 70]. Currently, there are several pathways that contribute to the initiation of FASN cytotoxicity. One is where FASN inhibition initiates a more effective apoptosis in cells with nonfunctioning p53 protein compared to those cells with functioning p53 protein, which occurs concurrently with cytostatic response [24, 32, 59, 62]. One is where HER2 overexpressed cells are also linked to FASN induced cytotoxicity. In addition, there are studies on ovarian cancer cell lines showing that FASN activity modulates Akt activation, and, at the same time, Akt activation regulates FASN expression, suggesting that the Akt activation protects cells against FASN inhibitor induced cell death (Figure 3) [35, 62–64].
2.6. Therapeutic Implication Progress of FASN in Cancer Treatment, Diagnosis, and Prevention
There are two unique characteristics of FASN that made it suitable for being an antitumor target: its tissue distribution and its enzymatic activities. FASN is highly expressed in breast cancer but not in nonlactating normal breast tissue [35, 47, 52, 81]. From the enzymatic activities aspect, it catalyzes the terminal step of de novo fatty acid synthesis, not affecting other important components of the lipid metabolism [34, 42, 68]. In addition to its multienzymatic functions characteristics, it contains seven catalytic domains that can be targeted, as mentioned before. Thus, using FASN as a target will influence the proliferating compartment of the breast while the nonproliferating compartment will remain unaffected [23, 35, 47].
3. Natural Product-Derived FASN Inhibitors
3.1. Single Compound
3.1.1. Single Domain
(1) KS Domain. Currently, there is limited amount of research on FASN inhibitors. Cerulenin is the first FASN inhibitor identified and is a natural metabolic product used in antibiotics [33, 34, 61, 77]. It is a noncompetitive inhibitor with FASN and covalently binds with the hydroxyl group on serine at the end of the KS domain, forming hydroxyl-beta-lactam, irreversibly inhibiting de novo fatty acid synthesis [63, 80]. Cerulenin mainly inhibits the synthesis of long chain fatty acids and only inhibits the growth of cancer cells while the normal cells remain unaffected [63, 80, 82]. However, the usage of Cerulenin is limited because of its unstable structure and high toxicity levels [80, 82, 83].
(2) TE Domain. Other FASN inhibitors that can potentially be used as cancer treatment drugs have been identified, such as Orlistat (1-(3-hexyl-4-oxooxetan-2-yl) tridecan-2-yl 2-formamido-4-methylpentanoate), a drug designed to treat obesity and marketed as a prescription in most countries . Recent research has shown that Orlistat may also act on the TE domain of the FASN [46, 48]. Currently, Orlistat is the only FASN inhibitor under clinical usage. Other derivatives from Orlistat, such as the beta-lactam derivatives of Orlistat identified, have shown good inhibitory effect on FASN activity [46, 48, 49]. Therefore, the development of Orlistat and its derivatives will be an important approach for future research on FASN inhibitors.
(3) KR Domain. Epigallocatechin-3-gallate (EGCG), a natural component of green tea, is one of the several natural plant-derived polyphenols identified to have an FASN inhibitory effect higher than that of C75 [83–85]. EGCG acts on the KR domain of the FASN and is a high micromolar time-dependent inhibitor [83, 86, 87]. EGCG has a prominent inhibitory effect because it not only acts on the FASN but also could inhibit HIF-1-alpha expression by blocking PI3K/Akt signaling pathway . Recently, EGCG has been developed as a tumor growth inhibitor and is used in breast cancer xenograft models. Even so, there are limitations for EGCG as an FASN inhibitor, and its FASN inhibition effect can still be improved upon [77, 83, 86, 87]. Prior experiments have shown that, after the strong acid and heating treatment of EGCG, FASN inhibition will be greatly increased, and this raises the possibility that the increased effect is due to the change in the chemical composition of catechin [83, 87]. However, the follow-up experiment showed that EGCG becomes unstable after strong acid and heat treatment [83, 86, 87]. The initial product is unstable as well, which makes it difficult to investigate its molecular composition and properties.
Other FASN inhibitors include urea-derived compounds such as GSK837149A and can specifically inhibit the KR domain of FASN .
3.1.2. Multiple Domains
In 2000, Lotfus and his fellow colleagues reported a small molecule, a structurally modified form of Cerulenin to be a novel FASN inhibitor, the C75 . It is a derivative of 3-carboxy-4-alkyl-2-methylenebutyrolactones that overcomes the toxicity of Cerulenin and performs a better specific inhibitory effect than Cerulenin [36, 90]. Research has shown that the inhibitory effect of C75 on FASN differs from that of Cerulenin [36, 49, 77, 90]. C75 inhibits FASN with a noncovalently reversible inhibition to the KS, ER, and ES domain of FASN [77, 90]. The mechanism, however, by which C75 inhibits cancer cell growth, is still unclear [80, 90]. In 2000, Kuhajda et al. demonstrated that C75 inhibits fatty acid synthesis inducing cancer cell apoptosis; however, more in-depth research is still needed [36, 81]. Although, compared to other FASN inhibitors, much research has focused on C75, its clinical usage is limited due to its unstable nature .
3.1.3. Without Inhibitory Target Domain Studies
Icaritin (ICA), a prenylflavonoid derivative from Epimedium Genus, can effectively induce SKBr3, ER negative breast cancer cell line, and cell apoptosis and suppress cell growth in a concentration-dependent manner . Through the FASN/HER2 pathway, ICA is unable to upregulate PEA3 and downregulate HER2 . This suggests that ICA can be a potent FASN inhibitor and a potential anticancer drug for future development.
Amentoflavone, a natural biflavonoid isolated from S. tamariscina and abundantly found in the family Selaginellaceae, can suppress FASN expression at the protein and mRNA levels [62, 92]. S. tamariscina has a long history of being used for the treatment of advanced cancer in TCM [62, 78], as well as being used as an antioxidant, vasorelaxant, and anti-HIV and antiangiogenesis agent [62, 78, 93, 94]. In addition, despite amentoflavone’s FASN-inhibitory effect, which inhibits the translocation of SREBP-1 in SKBR3 cells, it can suppress HER2 activation and modulate Akt, mTOR, and JNK phosphorylation [32, 62, 94]. These actions induce cell death and increase the potential for using amentoflavone as a chemotherapeutic drug in the prevention or treatment of HER2-positive breast cancers .
3.2.1. With Inhibitory Target Domain Studies
Many researchers have found that EGCG extracted from grape seeds has a better inhibiting capacity compared to the effects of Monomeric catechin and epicatechin on FASN inhibition explored in previous research . Therefore, the separation of an active compound of grape seed extract will be meaningful for future studies in terms of its use as a novel FASN inhibitor, but there are many steps of extraction that will need to be further improved [83, 87, 95]. Thus, future investigation and study are needed to confirm the molecular mechanism of the increased FASN inhibition effect of EGCG as well as search for the conditions necessary to stabilize the formation of a high-activity and stable FASN inhibitor.
Coix seed extract from Semen Coicis is an oily substance, and its main active ingredient is a triglyceride containing four fatty acids . It is the first drug derived from TCM to go into clinical trials in the USA and has been proved to be an effective and safe TCM practice by preclinical antitumor studies and pharmacokinetics and safety studies . Yu et al. studied the Coix seed extract’s FASN inhibitory effect [96, 97]. Their experiment in vitro demonstrated that Coix seed extract, by inhibiting the KR and ER domain of FASN, could significantly inhibit FASN activity; in addition, their experiments in vivo also observed a significant FASN inhibitory effect in the liver produced by the Coix seed extract, which was accomplished by elevating LPL and HL activity in the plasma as well as affecting the G-6-PD activity [96, 97]. Thereby, Coix seed extract inhibits fatty acid synthesis and reduces formation of energy supplying tumor cell growth. Therefore, the antitumor effects of Coix seed extract are likely to be related to the inhibition of FASN activity [96, 97]. The study supports that FASN is a novel target for cancer therapy. Other studies of Coix seed extract show that it can inhibit tumor cell mitosis at G2/M phases, induce tumor cell apoptosis, inhibit tumor angiogenesis, and also upregulate FASN/Apo-1 gene expression and downregulate Bcl-2 gene expression of tumor cells. In addition, it can prevent anticancer drug resistance in tumor cells [96, 97]. The present study supports FASN as a novel target for cancer therapy and provides a theoretical foundation for the clinical application of Coix seed extract in cancer therapy. Continued studies are required for the future clinical uses of Coix seed extract as an FASN inhibiting anticancer drug.
A research by Wang et al. indicates that extracts of Fallopia multiflora can both reversibly and irreversibly inhibit FASN and exhibit a better inhibitory effect than both Cerulenin and C75 . Different than that of C75, which can only inhibit the KS domain of FASN, Fallopia multiflora extract can both inhibit the KR and the MT domain [98, 99]. However, due to the complexity of the herbal extract, the specific analog that exhibits the inhibitory effect has not yet been identified . Future research is required for a better understanding of the pharmacological activity and the inhibitory mechanism in order to develop better FASN inhibitors in the future. The screening results may provide direction for future research on novel FASN inhibitors from these categories of herbal medicines or compounds with similar chemical structures.
3.3. Only with Basic Inhibitory Effect Screening
Allium vegetables, represented by Allium fistulosum L., have been employed for a long time in traditional medical practice to treat a variety of diseases [100, 101]. In 1998, a case-control epidemiological study carried out in France suggested that higher onion intake was a protective factor for breast cancer . Recently, the anticarcinogenic potential of onion had been extensively studied by Wang et al. in 2013 . The study demonstrated that onion extract can inhibit FASN activity and induce MDA-MB-231 cells [64, 102] apoptosis as well as reducing intercellular lipid accumulation of 3T3-L1 adipocytes . This raised the potential of developing onion into a drug for the prevention and treatment of breast cancer as well as other obesity-related cancers [100–102].
Nephelium lappaceum L., commonly known as “rambutan”, is a tropical fruit of the Sapindaceae family whose antioxidant and antibacterial functions have been used for severe dysentery or as a carminative in dyspepsia [103, 104]. An article published in 2011 by Zhao et al. found that Nephelium lappaceum L. has an FASN inhibitory effect comparable to the commonly known natural FASN inhibitor EGCG . This revealed the potential of Nephelium lappaceum L. for being a promising FASN inhibitor. In addition, isolated glycosides from Nephelium lappaceum L., the oleane-type triterpene oligoglycosides, may also be another type of FASN inhibitor which may be developed into a novel chemoprevention and chemotherapy drug in the future [103, 104].
There have been years of research on FASN inhibitors and their role in breast cancer therapy in western medicine and recently Chinese Medicine has developed a similar research, with a focus on the weight loss effect of the inhibition of FASN using herbs . Tian et al. performed a screening of FASN inhibitor in 31 common herbal medicines and discovered a number of effective inhibitors in 2004 . Among the 31 herbs, Polygonum multiflorum (何首烏) [106, 107], Alpiniae officinarum (高良姜), Parasite scurrula (桑寄生), to name a few, showed strong FASN inhibitory effect and weight loss effect in animal models . Both Alpiniae officinarum and Parasite scurrula contain phenols such as flavone, increasing the potential for polyphenols to be an important active substance in terms of FASN inhibition [105, 108].
Recent research has screened potential Chinese herbal medicines for their inhibition effect on fatty acid synthase. Out of the 225 commonly prescribed herbal medications screened, 58 of them (25.78%) show strong (80–100%) inhibitory effect . Among those 58 strong potential FASN inhibitors, some pure compounds were found including alkaloid, anthraquinone, flavonoid (e.g., dried leaf of Apocynum venetum L. (羅麻布葉), spine of Gleditsia sinensis (皂角刺), Spatholobus suberectus (雞血藤) , Prunella vulgaris (夏枯草), Scutellaria baicalensis Georgi (黃芩), hawthorn fruit, and pagodatree flower), phenols, kaempferol, tannins (e.g., Melaphis chinensis (Bell.) (五倍子), the root of Sanguisorba officinalis L. (地榆), Rhuen palmatum L. (大黃), and mature seed of Litchi chinensis Sonn (荔枝核)), triterpenes, gallic acid, ursolic acid, paeoniflorin, and saponins [105, 109, 110]. These herbs are characterized, according to Chinese medicine theory, into those which have the effects of clearing away heat and toxic materials (Table 1), enriching the blood and invigorating the circulation of blood (Table 2), promoting health while promoting meridian and blood (Table 3), regulating Qi Flow (Table 4), and reducing phlegm and dehumidification (Table 5) and other effects (Table 6) including removing blood stasis and promoting the subsidence of swelling, analgesic, warming spleen and stomach for dispelling cold, and cooling blood to stop bleeding by their functions. Linoleic acid , some poly-unsaturated acid [50, 100], polyphenols , and flavones , among others, have all shown some FASN inhibitory effects, with some displaying better inhibiting effects than C75 .
4. Future Perspective and Conclusion
The de novo fatty acid synthesis is a distinct feature of cancer cells, distinguishing it from normal cells . The tumor cell’s intrinsic properties and the tumor microenvironment result in the metabolic alternation and adaptation of cancer cells. This lipid metabolism alternation and the high rate of de novo fatty acid synthesis allow cancer cells to sustain higher proliferation rates and rapid growth. Therefore, targeting the key enzyme of the fatty acid synthesis, the FASN, can be an important strategy for anticancer drug development.
4.1. CAM as the Important Trend in Cancer Treatment and the Superiority of TCM in FASN Inhibitors Development
Complementary and alternative medicine (CAM) has been a recent source of drug discovery in cancer research. A wide range of prescription drugs used for cancer treatment are derived from medicinal plants and 74% of those drugs were based on “folk medicine” . Among all CAM modalities, TCM has a long history of clinical practice and well-established theoretical approaches and also enjoys particular appreciation for its uses as an adjunct therapy to slow down the development of chemotherapy drug resistance and to relieve the unpleasant side effects of chemotherapy and radiotherapy . However, although TCM is appreciated for its efficiency and minimal side effect, there is still insufficient understanding of its mechanism as well as inadequate evidence for verifying its effectiveness [9, 15, 111]. Although both the standard cancer therapy and TCM have been used for decades in China for improving both the clinical outcome in cancer treatment and the quality of life of the surviving patients, [11, 111] due to insufficient quality control for herbal products and the shortage of randomized controlled trials (RCT), whether herbal medicines can indeed treat cancer remains controversial [10–12, 15].
Statistics have shown that out of the 260,000 to 300, 000 plant species in the world, only around 5,000 of them have been studied for their possible medical applications . With the long history of clinical based practice of Chinese herbal medicine and great number of histological document and case reports in cancer treatment, Chinese herbal medicine has a unique position in drug discovery for molecular targeting based therapeutic strategy [9–11, 15]. The research done on FASN inhibitors is receiving increasing amounts of attention from the media, since it was reported as a potential therapeutic target for both obesity and breast cancer. This has raised the question of whether there are any potent FASN inhibitors in Chinese herbal medicine or in any other natural product. The ongoing development of the FASN inhibitors screening strategy will provide a good platform for exploring and discovering inhibitors in natural products, which are more molecular target specific and contain lower toxicity levels. Chinese herbal medicine with its multiple active components is considered a promising source for the design of drugs that regulate multiple cellular signal pathways for cancer therapy. This leads us into a new era or anticancer drug development.
4.2. Future Potential of FASN Inhibitors in Cancer Treatment
As mentioned before, molecular targeted therapy has been attracting considerable attention in the research of cancer treatment. An ideal molecular target should be preferentially expressed or activated in malignant cells but not in normal cells, thus making FASN an attractive target for future research. With the progress of molecular and genetic technologies, a number of target inhibitors have been discovered either by synthesis or design. In FASN specific inhibition, C75 and EGCG are well known examples of inhibitors. However, their therapeutic efficacies are limited due to either their high toxic level or unstable nature. Therefore, seeking a more stable and potent drug as a target inhibitor will be an important future trend for research and development for oncologists.
In the future research for potential FASN inhibitors, there should be two main approaches: the first is to screen for individual herbal medicines and their active compounds and the other is to screen for traditional formulas or effective clinical experience-based formulas under the guidance of either TCM theory or modern pharmacology [9, 12]. On the basis of the theory of traditional Chinese medicine, the treatment of breast cancer with a focus on weight loss effect can follow two approaches: by smoothing liver and regulating Qi and by promoting blood circulation for removing blood stasis. Therefore, further research on herbal medicines and traditional formulas may be a promising method for the development of more potent anticancer drugs.
Over the past few decades, active compounds extracted from herbal medicines have received good responses clinically. The investigation of Chinese Herbal Medicine with weight loss effects, which may be related to inhibition of the fatty acid synthesis pathway, may be an advantageous approach for future research. It is worthwhile to investigate those herbal medicines commonly used in Traditional Prescription for antibreast cancer treatment as well, such as the root of Sanguisorba officinalis L. (地榆), Spatholobus suberectus (雞血藤), Pericarpium granati (石榴皮), the root of Paeonia lactiflora Pall. (白芍), Paeonia vaitchii Lynch (赤芍), and Paeonia suffruticosa Andr. (牡丹皮). Further studies on the inhibitory mechanisms and domains of these medicines, with their relatively good FASN inhibitory effect, will provide us with a much better understanding of cancer biology and equip us with the knowledge needed for better future implementation for future cancer chemotherapy and chemoprevention.
Currently, all of the basic screenings have only focused on the FASN inhibitory effect of one single herbal medicine. However, clinically, most of the Chinese herbal medications are prescribed as a combination of a number of herbal medicines, in the form of a decoction. There is limited research on the FASN inhibitory effect of TCM herbal decoctions. Some decoctions commonly prescribed to breast cancer patients have been found to be composed of several herbal medicines that have proven FASN inhibitory effects. As mentioned before, smoothing liver and regulating Qi and promoting blood circulation for removing blood stasis are two main ways to treat breast cancer under the guidance of TCM theory. Herein, we will give one example of TCM prescription with the effect of smoothing liver and regulating Qi (Tables 7-1); four examples (Tables 7-2,3,4,5) with the effect of promoting blood circulation for removing blood stasis; and one example with both of these two effects (Tables 7-6).
Unlike surgery, chemotherapy, and radiotherapy, which can have serious consequence on the human body, the practice and usage of Chinese herbal medicine in cancer therapy mobilize and regulate the body’s functions, enhancing the body’s ability to fight cancer. Therefore, Chinese herbal medicine may be more suitable for inoperable patients with advanced cancer, for those in intermittent periods of chemotherapy, or for patients in a postoperative recovery period. There has been an increase of attention on the research of Chinese herbal medicine in the prevention of cancer and inhibition of cancer metastasis. There is an impressive renaissance seeking for semisynthetic drugs or derivatives from natural compounds. Progress in this regard not only adds to the Chemical Bank but also leads to a better understanding of the chemical basis of Chinese herbal medicine for the treatment of cancer using drugs obtained from natural sources.
|FASN:||Fatty acid synthase|
|TCM:||Traditional chinese medicine|
|CAM:||Complementary and alternative medicine|
|BMI:||Body mass index|
|EGFR:||Epidermal growth factor receptor|
|SREBP1C:||Sterol regulatory element-binding protein 1c.|
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors thank Wujing Zhang from the University of Southern California and Emille Kohl from the University of Hong Kong for editorial assistance. The work was supported by the Seed Funding Programme for Basic Research, University of Hong Kong (104001763).
- A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
- P. Boyle and B. Levin, World Cancer Report, IARC Press, Lyon, France, 2008.
- R. Alteri, C. Barnes, A. Burke, et al., American Cancer Society. Breast Cancer Facts & Figures 2013-2014, American Cancer Society, 2013.
- A. R. Carmichael and T. Bates, “Obesity and breast cancer: a review of the literature,” Breast, vol. 13, no. 2, pp. 85–92, 2004.
- H. D. Nelson, B. Zakher, A. Cantor et al., “Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 156, no. 9, pp. 635–648, 2012.
- A. Montazeri, J. Sadighi, F. Farzadi et al., “Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study,” BMC Cancer, vol. 8, article 278, 2008.
- Agilent Technologies Affymetrix, Applied Biosystems, AstraZeneca, Novartis Oncology, Pfizer, and Roche Diagnostics, “The Third International Symposium on the Molecular Biology of Breast Cancer,” Breast Cancer Research, vol. 7, supplement 2, pp. S1–S62, 2005.
- E. Ernst, “Complementary and alternative medicine (CAM) and cancer: the kind face of complementary medicine,” International Journal of Surgery, vol. 7, no. 6, pp. 499–500, 2009.
- W. L. W. Hsiao and L. Liu, “The role of traditional Chinese herbal medicines in cancer therapy from TCM theory to mechanistic insights,” Planta Medica, vol. 76, no. 11, pp. 1118–1131, 2010.
- J.-J. Li, J.-P. Fu, and J. T. Li, “Chinese medicine approach in clinical practice for breast cancer survivors,” Chinese Journal of Integrative Medicine, vol. 4, pp. 308–315, 2011.
- S.-Y. Pan, S.-B. Chen, H.-G. Dong et al., “New perspectives on chinese herbal medicine (Zhong-Yao) research and development,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 403709, 2011.
- S. Wang, S. Penchala, S. Prabhu, J. Wang, and Y. Huang, “Molecular basis of traditional chinese medicine in cancer chemoprevention,” Current Drug Discovery Technologies, vol. 7, no. 1, pp. 67–75, 2010.
- D. J. Newman, G. M. Cragg, and K. M. Snader, “Natural products as sources of new drugs over the period 1981–2002,” Journal of Natural Products, vol. 66, no. 7, pp. 1022–1037, 2003.
- S. Miller, J. Stagl, D. B. Wallerstedt, M. Ryan, and P. J. Mansky, “Botanicals used in complementary and alternative medicine treatment of cancer: clinical science and future perspectives,” Expert Opinion on Investigational Drugs, vol. 17, no. 9, pp. 1353–1364, 2008.
- Z. Wang, N. Wang, J. Chen, and J. Shen, “Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 873175, 13 pages, 2012.
- X. F. Zhai, Z. Chen, B. Li et al., “Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial,” Journal of Integrative Medicine, vol. 11, pp. 90–100, 2013.
- M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011.
- Y. Shi and P. Burn, “Lipid metabolic enzymes: emerging drug targets for the treatment of obesity,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 695–710, 2004.
- R. Ballard-Barbash, S. Hunsberger, M. H. Alciati et al., “Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations,” Journal of the National Cancer Institute, vol. 101, no. 9, pp. 630–643, 2009.
- S. E. Zagami, N. Golmakani, F. H. Shandiz, and A. Saki, “Evaluating the relationship between body size and body shape with the risk of breast cancer,” Oman Medical Journal, vol. 28, pp. 389–394, 2013.
- X. L. Wang, C. X. Jia, L. Y. Liu, Q. Zhang, Y. Y. Li, and L. Li, “Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China,” World Journal of Surgical Oncology, vol. 11, article 71, 2013.
- L. Garrido-Sánchez, J. Vendrell, D. Fernández-García et al., “De novo lipogenesis in adipose tissue is associated with course of morbid obesity after bariatric surgery,” PLoS ONE, vol. 7, no. 2, Article ID e31280, 2012.
- R. Lupu and J. A. Menendez, “Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?” Endocrinology, vol. 147, no. 9, pp. 4056–4066, 2006.
- M. S. Strable and J. M. Ntambi, “Genetic control of de novo lipogenesis: role in diet-induced obesity,” Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 3, pp. 199–214, 2010.
- T. Mashima, H. Seimiya, and T. Tsuruo, “De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy,” British Journal of Cancer, vol. 100, no. 9, pp. 1369–1372, 2009.
- Q. Chen and Y. Zhang, “Effect of functional factors in the hull of camellia oleifera abel. On obesity and dyslipidemia,” China Academic Journal, 2011.
- B. P. Atshaves, G. G. Martin, H. A. Hostetler, A. L. McIntosh, A. B. Kier, and F. Schroeder, “Liver fatty acid-binding protein and obesity,” Journal of Nutritional Biochemistry, vol. 21, no. 11, pp. 1015–1032, 2010.
- Z. Suba, “Circulatory estrogen level protects against breast cancer in obese women,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, pp. 154–167, 2013.
- J. S. Varghese, D. J. Thompson, K. Michailidou et al., “Mammographic breast density and breast cancer: evidence of a shared genetic basis,” Cancer Research, vol. 72, no. 6, pp. 1478–1484, 2012.
- E. S. Pizer, J. Thupari, W. F. Han et al., “Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts,” Cancer Research, vol. 60, no. 2, pp. 213–218, 2000.
- W. Zhou, Y. Tu, P. J. Simpson, and F. P. Kuhajda, “Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells,” Oncogene, vol. 28, no. 33, pp. 2979–2987, 2009.
- X. Zhao, D. Feng, Q. Wang et al., “Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1,” Journal of Clinical Investigation, vol. 122, pp. 2417–2427, 2012.
- F. J. Asturias, J. Z. Chadick, I. K. Cheung et al., “Structure and molecular organization of mammalian fatty acid synthase,” Nature Structural and Molecular Biology, vol. 12, no. 3, pp. 225–232, 2005.
- A. Jayakumar, M.-H. Tai, W.-Y. Huang et al., “Human fatty acid synthase: properties and molecular cloning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 19, pp. 8695–8699, 1995.
- F. P. Kuhajda, “Fatty acid synthase and cancer: new application of an old pathway,” Cancer Research, vol. 66, no. 12, pp. 5977–5980, 2006.
- F. P. Kuhajda, E. S. Pizer, J. N. Li, N. S. Mani, G. L. Frehywot, and C. A. Townsend, “Synthesis and antitumor activity of an inhibitor of fatty acid synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3450–3454, 2000.
- S. S. Chirala and S. J. Wakil, “Structure and function of animal fatty acid synthase,” Lipids, vol. 39, no. 11, pp. 1045–1053, 2004.
- J. W. Clendening and L. Z. Penn, “Targeting tumor cell metabolism with statins,” Oncogene, vol. 31, pp. 4967–4978, 2012.
- R. J. DeBerardinis, “Is cancer a disease of abnormal cellular metabolism? New angles on an old idea,” Genetics in Medicine, vol. 10, no. 11, pp. 767–777, 2008.
- E. S. Pizer, F. D. Wood, H. S. Heine, F. E. Romantsev, G. R. Pasternack, and F. P. Kuhajda, “Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer,” Cancer Research, vol. 56, no. 6, pp. 1189–1193, 1996.
- Q. Fu, W. Cai, M. Wang, and Y. Wang, “Effects of inhibiting fatty acid synthase on the growth of colorectal cancer cells and its mechanism,” Chinese Journal of Gastroenterology, vol. 7, no. 4, pp. 202–205, 2002.
- J. A. Menendez and R. Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nature Reviews Cancer, vol. 7, no. 10, pp. 763–777, 2007.
- A. Georgiadi and S. Kersten, “Mechanisms of gene regulation by fatty acids,” Advances in Nutrition, vol. 3, pp. 127–134, 2012.
- I. Kelesidis, T. Kelesidis, and C. S. Mantzoros, “Adiponectin and cancer: a systematic review,” British Journal of Cancer, vol. 94, no. 9, pp. 1221–1225, 2006.
- F. P. Kuhajda, “AMP-activated protein kinase and human cancer: cancer metabolism revisited,” International Journal of Obesity, vol. 32, no. 4, pp. S36–S41, 2008.
- J. A. Menendez, L. Vellon, and R. Lupu, “Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene,” Annals of Oncology, vol. 16, no. 8, pp. 1253–1267, 2005.
- S. S. Chirala, A. Jayakumar, Z.-W. Gu, and S. J. Wakil, “Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 3104–3108, 2001.
- H.-Y. Chuang, Y.-F. Chang, and J.-J. Hwang, “Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal,” Biomedicine and Pharmacotherapy, vol. 65, no. 4, pp. 286–292, 2011.
- R. Flavin, S. Peluso, P. L. Nguyen, and M. Loda, “Fatty acid synthase as a potential therapeutic target in cancer,” Future Oncology, vol. 6, no. 4, pp. 551–562, 2010.
- S. K. Kachhap, P. P. Dange, R. H. Santani, S. S. Sawant, and S. N. Ghosh, “Effect of ω-3 fatty acid (docosahexanoic acid) on BRCA1 gene expression and growth in MCF-7 cell line,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 257–263, 2001.
- M. Wu, K. A. Harvey, N. Ruzmetov et al., “Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway,” International Journal of Cancer, vol. 117, no. 3, pp. 340–348, 2005.
- A. Vazquez-Martin, S. Ropero, J. Brunet, R. Colomer, and J. A. Menendez, “Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells,” Oncology reports, vol. 18, no. 4, pp. 973–980, 2007.
- E. S. Pizer, F. J. Chrest, J. A. DiGiuseppe, and W. F. Han, “Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines,” Cancer Research, vol. 58, no. 20, pp. 4611–4615, 1998.
- G. Gago, L. Diacovich, A. Arabolaza, S.-C. Tsai, and H. Gramajo, “Fatty acid biosynthesis in actinomycetes,” FEMS Microbiology Reviews, vol. 35, no. 3, pp. 475–497, 2011.
- A. Vazquez-Martin, R. Colomer, J. Brunet, and J. A. Menendez, “Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting “HER2 super-expression” occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells,” International Journal of Oncology, vol. 31, no. 4, pp. 769–776, 2007.
- S. Lu, G. Yu, Y. Zhu, and M. C. Archer, “Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation,” International Journal of Cancer, vol. 116, no. 6, pp. 847–852, 2005.
- W. Zhou, P. J. Simpson, J. M. McFadden et al., “Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells,” Cancer Research, vol. 63, no. 21, pp. 7330–7337, 2003.
- V. Fritz and L. Fajas, “Metabolism and proliferation share common regulatory pathways in cancer cells,” Oncogene, vol. 29, no. 31, pp. 4369–4377, 2010.
- S. M. Hadad, D. G. Hardie, V. Appleyard, and A. M. Thompson, “Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle,” Clinical and Translational Oncology, 2013.
- Z.-Y. Wang, D.-M. Wang, T. Y. Loo et al., “Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 751–758, 2011.
- Y. Y. Wang, F. P. Kuhajda, J. Li et al., “Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer,” Journal of Experimental Therapeutics and Oncology, vol. 4, no. 2, pp. 101–110, 2004.
- J. S. Lee, J. Y. Sul, J. B. Park et al., “Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells,” Phytotherapy Research, vol. 27, pp. 713–720, 2013.
- J. A. Menendez, I. Mehmi, V. A. Verma, P. K. Teng, and R. Lupu, “Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation,” Molecular Carcinogenesis, vol. 41, no. 3, pp. 164–178, 2004.
- P. D. Schley, H. B. Jijon, L. E. Robinson, and C. J. Field, “Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells,” Breast Cancer Research and Treatment, vol. 92, no. 2, pp. 187–195, 2005.
- W.-X. Tian, R.-F. Jiang, H.-B. Wu, Y.-H. Shi, and Y.-H. Wang, “The substrate inhibition by NADPH and kinetics of fatty acid synthase from duck liver,” Chinese Biochemical Journal, vol. 10, no. 4, pp. 413–419, 1994.
- T. Maier, S. Jenni, and N. Ban, “Architecture of mammalian fatty acid synthase at 4.5 å resolution,” Science, vol. 311, no. 5765, pp. 1258–1262, 2006.
- J. A. Menendez, R. Colomer, and R. Lupu, “Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?” Medical Hypotheses, vol. 64, no. 2, pp. 342–349, 2005.
- L. Eissing, T. Scherer, K. Todter et al., “De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health,” Nature Communications, vol. 4, p. 1528, 2013.
- A. Rinke, H.-H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009.
- A. T. Willingham, Q. L. Deveraux, G. M. Hampton, and P. Aza-Blanc, “RNAi and HTS: exploring cancer by systematic loss-of-function,” Oncogene, vol. 23, no. 51, pp. 8392–8400, 2004.
- R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011.
- T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001.
- D. A. Tennant, R. V. Durán, and E. Gottlieb, “Targeting metabolic transformation for cancer therapy,” Nature Reviews Cancer, vol. 10, no. 4, pp. 267–277, 2010.
- I. J. Lodhi, X. Wei, and C. F. Semenkovich, “Lipoexpediency: De novo lipogenesis as a metabolic signal transmitter,” Trends in Endocrinology and Metabolism, vol. 22, no. 1, pp. 1–8, 2011.
- F. Podo, “Tumour phospholipid metabolism,” NMR in Biomedicine, vol. 12, pp. 413–439, 1999.
- M. Hilvo, S. Gade, T. Hyotylainen et al., “Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients,” International Journal of Cancer, vol. 134, no. 4, pp. 1725–1733, 2013.
- T. Puig, A. Vázquez-Martín, J. Relat et al., “Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75,” Breast Cancer Research and Treatment, vol. 109, no. 3, pp. 471–479, 2008.
- J. S. Lee, M. S. Lee, W. K. Oh, and J. Y. Sul, “Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells,” Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1427–1432, 2009.
- F. P. Kuhajda, K. Jenner, F. D. Wood et al., “Fatty acid synthesis: a potential selective target for antineoplastic therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 14, pp. 6379–6383, 1994.
- A. Kawaguchi, H. Tomoda, S. Nozoe, S. Omura, and S. Okuda, “Mechanism of action of cerulenin on fatty acid synthetase: effect of cerulenin on iodoacetamide-induced malonyl-coa decarboxylase activity,” Journal of Biochemistry, vol. 92, no. 1, pp. 7–12, 1982.
- F. P. Kuhajda, “Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology,” Nutrition, vol. 16, no. 3, pp. 202–208, 2000.
- J. N. Thupari, M. L. Pinn, and F. P. Kuhajda, “Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity,” Biochemical and Biophysical Research Communications, vol. 285, no. 2, pp. 217–223, 2001.
- X. Wang and W. Tian, “Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase,” Biochemical and Biophysical Research Communications, vol. 288, no. 5, pp. 1200–1206, 2001.
- W. P. Xiao, R. Zhang, and Y. H. Sun, “Enhancement of inhibitory activity of green tea extract on fatty acid synthase by hydrogen ion,” Chinese Journal of Biochemistry and Molecular Biology, vol. 22, pp. 234–238, 2006.
- Z. Rui, X. Wen-Ping, and T. Wei-Xi, “Inhibitory effects of green tea extract on fatty acid synthase,” Journal of Yunnan University, vol. 26, pp. 42–47, 2004.
- M.-H. Pan, C.-C. Lin, J.-K. Lin, and W.-J. Chen, “Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling,” Journal of Agricultural and Food Chemistry, vol. 55, no. 13, pp. 5030–5037, 2007.
- T. Puig Miquel, J. Relat, P. F. Marrero, D. Haro, J. Brunet, and R. Colomer, “Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals,” Anticancer Research, vol. 28, no. 6, pp. 3671–3676, 2008.
- M. J. Vázquez, W. Leavens, R. Liu et al., “Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction,” FEBS Journal, vol. 275, no. 7, pp. 1556–1567, 2008.
- T. M. Loftus, D. E. Jaworsky, C. L. Frehywot et al., “Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors,” Science, vol. 288, no. 5475, pp. 2379–2381, 2000.
- J. N. Thupari, L. E. Landree, G. V. Ronnett, and F. P. Kuhajda, “C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 14, pp. 9498–9502, 2002.
- Y. Zhang, “Induction of cancer cell apoptosis and growth inhibition by icaritin is associated with its ability to suppress fatty acid synthase activity,” China Academic Journal, 2009.
- G. K. Dae, H. Y. Ming, H. Oh, H. L. Dae, and S. L. Ho, “Vasorelaxation by amentoflavone isolated from Selaginella tamariscina,” Planta Medica, vol. 70, no. 8, pp. 718–722, 2004.
- Y.-M. Lin, H. Anderson, M. T. Flavin et al., “In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora,” Journal of Natural Products, vol. 60, no. 9, pp. 884–888, 1997.
- A. Mora, M. Paya, J. L. Rios, and M. J. Alcaraz, “Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation,” Biochemical Pharmacology, vol. 40, no. 4, pp. 793–797, 1990.
- W.-Y. Wu and Q.-G. Yu, “Grape seed extract in the fatty acid synthase inhibitors, chemical composition and activity determination,” Chinese Academic Journal, vol. 6, 2008.
- F. Yu, J. Gao, Y. Zeng, and C.-X. Liu, “Inhibition of Coix seed extract on fatty acid synthase, a novel target for anticancer activity,” Journal of Ethnopharmacology, vol. 119, no. 2, pp. 252–258, 2008.
- W.-A. Ding, M. Du, and Y. Chen, “Study of coix seed chemical composition and its mechanism of tumor and its prevention,” Jilin Journal of Traditional Chinese Medicine, vol. 12, 2012.
- L. Y. Wang, F. Le, N. Wang et al., “Alteration of fatty acid metabolism in the liver, adipose tissue, and testis of male mice conceived through assisted reproductive technologies: fatty acid metabolism in ART mice,” Lipids in Health and Disease, vol. 12, article 5, 2013.
- Y. J. Choi, Y. Yoon, H. S. Choi et al., “Effects of medicinal herb extracts and their components on steatogenic hepatotoxicity in Sk-Hep1 cells,” Toxicology Research, vol. 27, pp. 211–216, 2011.
- B. Challier, J.-M. Perarnau, and J.-F. Viel, “Garlic, onion and cereal fibre as protective factors for breast cancer: a French case-control study,” European Journal of Epidemiology, vol. 14, no. 8, pp. 737–747, 1998.
- A. Sengupta, S. Ghosh, and S. Bhattacharjee, “Allium vegetables in cancer prevention: an overview,” Asian Pacific Journal of Cancer Prevention, vol. 5, no. 3, pp. 237–245, 2004.
- Y. Wang, W. X. Tian, and X. F. Ma, “Inhibitory effects of onion (Allium cepa L.) extract on proliferation of cancer cells and adipocytes via inhibiting fatty acid synthase,” Asian Pacific Journal of Cancer Prevention, vol. 13, pp. 5573–5579, 2012.
- C. Y. Ragasa, R. D. De Luna, W. C. Cruz Jr., and J. A. Rideout, “Monoterpene lactones from the seeds of Nephelium lappaceum,” Journal of Natural Products, vol. 68, no. 9, pp. 1394–1396, 2005.
- Y.-X. Zhao, W.-J. Liang, H.-J. Fan et al., “Fatty acid synthase inhibitors from the hulls of Nephelium lappaceum L,” Carbohydrate Research, vol. 346, no. 11, pp. 1302–1306, 2011.
- W.-X. Tian, L.-C. Li, X.-D. Wu, and C.-C. Chen, “Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase,” Life Sciences, vol. 74, no. 19, pp. 2389–2399, 2004.
- J.-B. Sun, X.-G. Lu, and J.-S. Tang, “The effect of compound recipe TFR combined with exercise on the activity of FAS to diet-induced hypercholesteremia rats,” Journal of Huaiyin Teachers College, vol. 7, pp. 64–68, 2008.
- Y. Y. Zhang, F. Z. Zhang, L. Y. Sun, and X. Z. Wang, “Inhibition to fatty acid synthase from human breast cancer cell with extract of Tuber Fleeceflower root in vitro,” Journal of Qiqihar Medical College, vol. 25, pp. 1102–1104, 2004.
- W.-X. Tian, “Inhibition of fatty acid synthase by polyphenols,” Current Medicinal Chemistry, vol. 13, no. 8, pp. 967–977, 2006.
- X. F. Ma, Y. Liu, and S. G. Zhang, “Relationship between pharmic character of warm/cold traditional Chinese medicines and their inhibition to fatty acid synthase,” Journal of Graduate University of Chinese Academy of Sciences, vol. 29, pp. 699–706, 2012.
- H. Y. Song, L. Zhang, J. L. Pan, L. L. Yang, and G. Ji, “Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis,” Journal of Integrative Medicine, vol. 11, pp. 262–268, 2013.
- H. S. Parekh, G. Liu, and M. Q. Wei, “A new dawn for the use of traditional Chinese medicine in cancer therapy,” Molecular Cancer, vol. 8, article 21, 2009.